Cognition Therapeutics Q3 2026 Net Loss Narrows 16% to $4.15 Million

• Cognition Therapeutics’ third-quarter 2026 net loss narrowed 16% year over year to $4.15 million.
• Grant income more than doubled to $2.97 million, while research and development expenses rose 36% to $5.12 million year over year.
• Cash, cash equivalents and restricted cash equivalents totaled $31.48 million at September 30, with funding expected into the fourth quarter of 2027.
• The company aligned with the FDA on primary and key secondary endpoints for a planned Phase 3 zervimesine trial in Lewy body dementia.
• Top-line results from the Phase 2 START study in mild cognitive impairment and early Alzheimer’s disease are expected in the second half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cognition Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050600PRIMZONEFULLFEED9870800) on November 05, 2026, and is solely responsible for the information contained therein.